In IPF, moderate or high levels of CXCL13 in the blood correlate with annual changes in FVC, DLCO, TLC, and the total ILD lesions, suggesting that CXCL13 may be a predictive biomarker for the outcomes of patients with IPF [318]. This evidence concerns the gene CXCL13 and idiopathic pulmonary fibrosis.